Rating
Title	Analysis of human immunodeficiency virus type 1 drug resistance in children receiving nucleoside analogue reverse-transcriptase inhibitors plus nevirapine, nelfinavir, or ritonavir
Alternative Title	HIV-1 drug resistance in children in PACTG 377
Author	Eshleman, Susan H.;Krogstad, Paul;Jackson, J. Brooks;Wang, You-Gan;Lee, Sophia;Wei, Lee-Jen;Cunningham, Shawn;Wantman, Michael;Wiznia, Andrew;Johnson, George;Nachman, Sharon;Palumbo, Paul;Pediatric AIDS Clinical Trials Group 377
Contributor(s)	Journal of Infectious Diseases (Publisher)
Date	2001-06-15
Subject.MeSH	HIV-1 Anti-HIV Agents HIV Infections Drug Resistance, Microbial Antiretroviral Therapy, Highly Active Genotype Mutation Child Reverse Transcriptase Inhibitors RNA, Viral Nevirapine Nelfinavir Ritonavir Stavudine Treatment Failure Viral Load Clinical Trail
Subject.LCSH	HIV (Viruses);HIV infections;Immunological deficiency syndromes in children;Drug resistance;Highly active antiretroviral therapy;Genes;Mutation (Biology);Children;Reverse transcriptase;Clinical trials;Infectious Diseases Society of America
Description	Article written by researchers from the Department of Pathology, Johns Hopkins Medical Institutions;Department of Pediatrics, University of California, Los Angeles School of Medicine;Statistical Data Analysis Center, Harvard School of Public Health;Department of Pediatrics, Jacobi Medical Center, Albert Einstein College of Medicine;Department of Pediatrics, State University of New York, Stony Brook;Department of Pediatrics, Medical University of South Carolina;and Department of Pediatrics, University of Medicine and Dentistry of New Jersey. Published in The Journal of Infectious Diseases, June 15, 2001, volume 183, pages 1732-1738. Includes abstract, references, and tables.
Collection	MUSC Faculty Journal Articles
Contributing Institution	Waring Historical Library (MUSC)
Date Digital	2015-09
Rights	Copyright 2001, Infectious Diseases Society of America (IDSA). All rights reserved.
Language	English
Type	Text
Format	application/pdf
Media Type	Periodicals
Resource Identifier	fja_0030_2005
Abstract	In Pediatric AIDS Clinical Trials Group 377, antiretroviral therapy-experienced children were randomized to 4 treatment arms that included different combinations of stavudine, lamivudine (3TC), nevirapine (Nvp), nelfinavir (Nfv), and ritonavir (Rtv). Previous treatment with zidovudine (Zdv), didanosine (ddI), or zalcitabine (ddC) was acceptable. Drug resistance (R) mutations were assessed before study treatment (baseline) and at virologic failure. ZdvR, ddIR, and ddCR mutations were detected frequently at baseline but were not associated with virologic failure. Children with drug resistance mutations at baseline had greater reductions in virus load over time than did children who did not. NvpR and 3TCR mutations were detected frequently at virologic failure, and NvpR mutations were more common among children receiving 3-drug versus 4-drug Nvp-containing regimens. Children who were maintained on their study regimen after virologic failure accumulated additional NvpR and 3TCR mutations plus RtvR and NfvR mutations. However, RtvR and NfvR mutations were detected at unexpectedly low rates.

Analysis of human immunodeficiency virus type 1 drug resistance in children receiving nucleoside analogue reverse-transcriptase inhibitors plus nevirapine, nelfinavir, or ritonavir

Description

Tags

Comments